샘플 요청 목록

 카트 문의
시장보고서
상품코드
1869709

에피네프린 시장 규모, 점유율과 동향 분석 리포트 : 제품별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

Epinephrine Market Size, Share & Trends Analysis Report By Product, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

에피네프린 시장 요약

세계의 에피네프린 시장 규모는 2024년에 28억 7,000만 달러로 평가되며, 2030년까지 60억 8,000만 달러에 달할 것으로 예측됩니다.

2025-2033년에는 CAGR 8.71%로 성장할 전망입니다.이러한 성장은 알레르기 환자 증가, 아나필락시스에 대한 대중의 인식 증가, 학교 및 공공시설의 '에피네프린 비축' 정책 확대가 수요를 견인한 것으로 분석됩니다.

시장 동향은 기존의 주사제 형태를 넘어 다양화를 보이고 있으며, 편의성과 복약 순응도 강화을 약속하는 무침주사, 비강분무, 경구용 필름 등 대체투여시스템이 강세를 보이고 있습니다. 생명을 위협하는 아나필락시스에 대한 인식이 높아지고 의료 인프라가 개선되면서 시장 확대가 가속화되고 있습니다. 2025년 6월, WHO 유럽지역 사무국과 유럽호흡기학회의 공동 보고서에 따르면 천식과 COPD를 포함한 만성 호흡기 질환(CRD)을 앓고 있는 WHO 유럽 인구가 8,170만 명에 달하며, 더 많은 수의 환자가 진단되지 않은 것으로 추정됩니다. 이는 적시에 개입이 필요한 환자군의 중요성을 강조하고 있습니다.

제네릭 의약품과 바이오시밀러 제품의 진입으로 가격 경쟁이 심화되는 반면, 접근성은 향상되고 있으며, 브랜드 제조업체들은 스마트 커넥티드 디바이스 및 환자 지원 프로그램을 통해 차별화를 꾀하고 있습니다. 또한 신흥 경제국의 지역 시장 확대, 전략적 제휴, 공급망 현지화 등이 주요 관심사가 되고 있으며, 에피네프린 분야 전반에 걸쳐 혁신, 경제성, 대중의 접근성 확대에 대한 요구가 반영되고 있습니다.

심각한 알레르기 반응에 대한 인식이 높아지고 아나필락시스 유병률이 전 세계에서 증가함에 따라 에피네프린은 응급 치료의 중요한 수단으로서 에피네프린 수요를 견인하고 있습니다. 생명을 위협하는 알레르기 반응에 대한 인식과 관리에 초점을 맞춘 교육 활동의 강화가 이러한 추세를 지원하고 있습니다.

자주 묻는 질문

  • 2024년 에피네프린 시장 규모는 어떻게 되나요?
  • 2030년 에피네프린 시장 규모는 어떻게 예측되나요?
  • 2025-2033년 에피네프린 시장의 CAGR은 어떻게 되나요?
  • 에피네프린 시장의 주요 성장 요인은 무엇인가요?
  • 에피네프린 시장에서 어떤 대체 투여 시스템이 강세를 보이고 있나요?
  • 에피네프린 시장의 경쟁 구도는 어떻게 되나요?

목차

제1장 조사 방법과 범위

제2장 개요

제3장 에피네프린 시장 변수, 동향, 범위

  • 시장 계통 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 비즈니스 환경 분석
    • 업계 분석 - Porter's Five Forces 분석
    • PESTLE 분석
    • 파이프라인 분석

제4장 에피네프린 시장 : 제품의 비즈니스 분석

  • 제품의 시장 점유율, 2024년 및 2033년
  • 제품의 부문 대시보드
  • 시장 규모, 예측, 동향 분석(제품별, 2021-2033년)
  • 자동 주사기(에피네프린 자동 주사기-EAI)
  • 프리필드 시린지와 일회용 주사기
  • 앰플/바이알(병원용 주사제)

제5장 에피네프린 시장 : 유통 채널 비즈니스 분석

  • 유통 채널 시장 점유율, 2024년 및 2033년
  • 유통 채널 부문 대시보드
  • 시장 규모, 예측, 동향 분석, 유통 채널별, 2021-2033년
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제6장 에피네프린 시장 : 지역 추정·동향 분석

  • 지역 시장 점유율 분석, 2024년 및 2033년
  • 지역의 시장 대시보드
  • 시장 규모와 예측 동향 분석, 2021-2033년 :
  • 북미
    • 국가별, 2021-2033년
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제7장 경쟁 구도

  • 참가자 개요
  • 기업의 시장 현황 분석
  • 기업 분류
  • 전략 지도제작
  • 기업 개요
    • Viatris Inc.
    • Kaleo, Inc.
    • Amneal Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Ltd
    • Pfizer Inc
    • Fresenius Kabi AG
    • Baxter International Inc.
    • BPI Labs/Generic Injectables Manufacturers
    • Kindeva Drug Delivery
    • Sandoz(a Novartis Division)
KSA 25.12.11

Epinephrine Market Summary

The global epinephrine market size was valued at USD 2.87 billion in 2024 and is projected to reach USD 6.08 billion by 2030, growing at a CAGR of 8.71% from 2025 to 2033. The growth is attributed to rising allergy prevalence, greater public awareness of anaphylaxis, and expanding "stock epinephrine" policies in schools and public venues drive demand.

Market trends point toward diversification beyond traditional injectable forms, with strong momentum for needle-free and alternative delivery systems such as intranasal sprays and oral films that promise greater convenience and compliance. Growing awareness of life-threatening anaphylaxis and improvements in healthcare infrastructure are fueling market expansion. In June 2025, a joint report by WHO Europe and the European Respiratory Society estimated that 81.7 million people in the WHO European Region are living with chronic respiratory diseases (CRDs), including asthma and COPD, with many additional cases remaining undiagnosed. This highlights the significant patient population requiring timely intervention.

The entry of generics and biosimilar equivalents is intensifying price competition while improving accessibility, prompting branded players to differentiate through smart, connected devices and patient-support programs. Additionally, regional market expansion in emerging economies, strategic partnerships, and supply-chain localization are becoming key focus areas, reflecting an overall trend toward innovation, affordability, and broader public access within the epinephrine segment.

Increasing awareness of severe allergic reactions and the rising global prevalence of anaphylaxis are driving demand for epinephrine as a critical emergency treatment. Enhanced education initiatives focusing on recognizing and managing life-threatening allergic episodes have supported this trend.

Global Epinephrine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global epinephrine market report based on product, distribution channel, and region:

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Auto-Injectors (Epinephrine Auto-Injectors - EAIs)
  • Prefilled Syringes & Disposable Injectors
  • Ampoules / Vials (Hospital Injectables)
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Epinephrine Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Epinephrine Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Billion)
  • 4.4. Auto-Injectors (Epinephrine Auto-Injectors - EAIs)
    • 4.4.1. Auto-Injectors (Epinephrine Auto-Injectors - EAIs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.5. Prefilled Syringes & Disposable Injectors
    • 4.5.1. Prefilled Syringes & Disposable Injectors Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.6. Ampoules / Vials (Hospital Injectables)
    • 4.6.1. Ampoules / Vials (Hospital Injectables) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Epinephrine Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.6. Online Pharmacies
    • 5.6.1. Online Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Epinephrine Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Epinephrine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Type Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Type Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Type Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5. Europe
    • 6.5.1. Europe Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Type Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Type Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Type Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Type Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Type Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Type Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Type Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Type Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Type Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Type Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Type Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Type Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Type Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Type Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.7. Latin America
    • 6.7.1. Latin America Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Type Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Type Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Type Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Type Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Type Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Type Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Epinephrine Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Viatris Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Kaleo, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Amneal Pharmaceuticals, Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Teva Pharmaceutical Industries Ltd
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Pfizer Inc
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Fresenius Kabi AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Baxter International Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. BPI Labs / Generic Injectables Manufacturers
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Kindeva Drug Delivery
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sandoz (a Novartis Division)
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제